EMA Adopts Five Product-Specific Bioequivalence Guidances

International Pharmaceutical Regulatory Monitor
A A
The European Medicines Agency adopted five product-specific guidances, effective Jan. 1, 2018, outlining requirements for establishing bioequivalence, including clinical study design.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor